Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively
This placebo-controlled, double-blind, cross-over, within-subjects study (n=18) investigated whether ayahuasca (42 & 59.5mg/70kg DMT) impairs the ability to filter out unnecessary sensory information in healthy volunteers. This yielded mixed results, with evidence to support that ayahuasca impairs sensorimotor gating in the domain of auditory suppression, but not within the domain of visual-induced prepulse inhibition of the startle reflex.
Authors
- Jordi Riba
- Maria Barbanoj
Published
Abstract
Rationale
Ayahuasca, a South American psychotropic plant tea, combines the psychedelic agent and 5-HT(2A/2C) agonist N, N-dimethyltryptamine (DMT) with beta-carboline alkaloids showing monoamine oxidase-inhibiting properties. Current human research with psychedelics and entactogens has explored the possibility that drugs displaying agonist activity at the 5-HT(2A/2C) sites temporally disrupt inhibitory neural mechanisms thought to intervene in the normal filtering of information. Suppression of the P50 auditory evoked potential (AEP) and prepulse inhibition of startle (PPI) are considered operational measures of sensory (P50 suppression) and sensorimotor (PPI) gating. Contrary to findings in lower animals, unexpected increases in sensorimotor gating have been found in humans following the administration of the serotonergic psychedelic psilocybin and the serotonin releaser 3,4-methylenedioxymethamphetamine (MDMA). In addition, to our knowledge P50 suppression has not been assessed previously in humans following the administration of a 5-HT(2A/2C) agonist.
Objectives
To assess the effects of the acute administration of ayahuasca on P50 suppression and PPI in humans, in order to evaluate the drug's modulatory actions on these measures of sensory and sensorimotor gating.
Methods
Eighteen healthy volunteers with prior experience of psychedelic drug use participated in a clinical trial in which placebo or ayahuasca doses (0.6 mg and 0.85 mg DMT/kg body weight) were administered according to a double-blind, cross-over balanced design. P50 and startle reflex (pulse-alone and 60 ms, 120 ms, 240 ms and 2000 ms prepulse-to-pulse intervals) recordings were undertaken at 1.5 h and 2 h after drug intake, respectively.
Results
Ayahuasca produced diverging effects on each of the two gating measures evaluated. Whereas significant dose-dependent reductions of P50 suppression were observed after ayahuasca, no significant effects were found on the startle response, its habituation rate, or on PPI at any of the prepulse-to-pulse intervals studied.
Conclusion
The present findings indicate, at the doses tested, a decremental effect of ayahuasca on sensory gating, as measured by P50 suppression, and no distinct effects on sensorimotor gating, as measured by PPI.
Research Summary of 'Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively'
Introduction
Ayahuasca is a traditional Amazonian plant brew that combines the psychedelic N,N-dimethyltryptamine (DMT), a 5-HT2A/2C agonist, with beta-carboline alkaloids that inhibit monoamine oxidase (MAO), thereby enabling oral activity of DMT. Earlier research has suggested that serotonergic psychedelics, dopaminergic agonists and NMDA antagonists can transiently alter neural mechanisms that normally filter sensory information. Two operational neurophysiological measures of such gating are suppression of the P50 auditory evoked potential (P50 suppression), taken as an index of sensory gating with hippocampal involvement, and prepulse inhibition of the startle reflex (PPI), an index of sensorimotor gating modulated by a forebrain–brainstem circuit. Prior human pharmacological challenge studies had examined PPI after some serotonergic drugs but, according to the authors, P50 suppression had not been previously assessed in humans following a 5-HT2A/2C agonist challenge. Riba and colleagues set out to evaluate the acute effects of ayahuasca on both P50 suppression and PPI in a single sample of healthy volunteers. The study aimed to determine whether ayahuasca would differentially modulate sensory versus sensorimotor gating and to relate any neurophysiological changes to the subjective psychedelic experience induced by the beverage.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Riba, J., Rodríguez-Fornells, A., & Barbanoj, M. (2002). Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology, 165(1), 18-28. https://doi.org/10.1007/s00213-002-1237-5
References (3)
Papers cited by this study that are also in Blossom
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Cited By (21)
Papers in Blossom that reference this study
Chenhall, R., Sarris, J., Bouso, J. C. et al. · Psychoactives (2023)
Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)
Herrmann, Z., Earleywine, M., De Leo, J. et al. · Journal of Psychoactive Drugs (2022)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Schenberg, E. E., Gerber, K. · Transcultural Psychiatry (2022)
Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)
Varley, T. F., Carhart-Harris, R., Roseman, L. et al. · NeuroImage (2020)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Millière, R. · Frontiers in Human Neuroscience (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Show all 21 papersShow fewer
Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)
Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)
Dos Santos, R. G., Balthazar, F. M., Bouso, J. C. et al. · Journal of Psychopharmacology (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Maqueda, A. E., Valle, M., Addy, P. H. et al. · International Journal of Neuropsychopharmacology (2015)
Bogenschutz, M. P. · Current Drug Abuse Reviews (2013)
Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)
Halberstadt, A. L., Nicholas, C. R. · Handbook of Behavioral Neuroscience (2010)
Vollenweider, F. X., Csomor, P. A., Knappe, B. et al. · Neuropsychopharmacology (2007)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.